Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
PPCB
vs
S&P 500
PPCB
S&P 500
Over the past 12 months, PPCB has underperformed S&P 500, delivering a return of -81% compared to S&P 500's +11% growth.
Stocks Performance
PPCB vs S&P 500
Performance Gap
PPCB vs S&P 500
Performance By Year
PPCB vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Propanc Biopharma Inc
Glance View
Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The firm has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.